In 2019, another study of combination therapy using 3–5 MBq [225Ac]Ac-PSMA-617 and 3.5–7.5 GBq [177Lu]Lu-PSMA-617 in 30 patients with end-stage PCa was reported. This evidence concerns the gene FOLH1 and posterior cortical atrophy.